Anal cancer
Osteoarthritis: significant improvement in pain and physical function with Tanezumab
Results from a phase 3 study evaluating Tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis ( OA...
Combined modality treatment associated with improved overall survival in pediatric Hodgkin lymphoma patients
Research from Rutgers Cancer Institute of New Jersey ( Unined States ) has shown improved overall survival at five years...
Atezolizumab associated with Bevacizumab in non-clear cell renal cell carcinoma and clear cell renal cell carcinoma with sarcomatoid differentiation
Non-clear cell renal cell carcinoma ( NccRCC ) and clear cell renal cell carcinoma with sarcomatoid differentiation ( sccRCC )...
Ibrance: FDA has expanded approved use of metastatic breast cancer treatment to include male patients
The FDA ( U.S. Food and Drug Administration ) has extended the indication of Ibrance ( Palbociclib ) capsules in...
Venclexta as a chemotherapy-free combination regimen for previously untreated chronic lymphocytic leukemia patients, approved by FDA
The U.S. Food and Drug Administration ( FDA ) has approved Venclexta ( Venetoclax ) in combination with Obinutuzumab (...
FDA has approved Piqray, the first PI3K inhibitor for HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer
The FDA ( U.S. Food and Drug Administration ) has approved Piqray ( Alpelisib ) tablets, to be used in...
Lynparza tablets for the treatment of Platinum-sensitive relapsed ovarian cancer regardless of BRCA status: approved in European Union
The European Medicines Agency ( EMA ) has approved Lynparza ( Olaparib ) tablets ( 300mg twice daily ) for...
European Commission has approved Cabometyx for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma
The European Commission ( EC ) has approved Cabometyx ( Cabozantinib ) 20, 40, 60 mg for the first-line treatment...
Olaparib in combination with Abiraterone delays disease progression in metastatic castration-resistant prostate cancer
Data, presented at 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting, showed clinical improvement in median radiologic...
Non-metastatic castration-resistant prostate cancer: Enzalutamide delays metastasis-free survival versus placebo without worsening HRQoL in PROSPER trial
The phase 3 PROSPER trial has showed a statistically significant improvement in metastasis-free survival ( MFS ) with Enzalutamide (...
Tagrisso for 1st-line treatment of EGFR-mutated non-small cell lung cancer, approved in European Union
The European Commission has granted marketing authorisation for Tagrisso ( Osimertinib ), a third-generation, irreversible EGFR-TKI, as monotherapy for the...
ADXS-PSA plus Pembrolizumab in metastatic castration-resistant prostate cancer: KEYNOTE-046
ADXS-PSA, an attenuated Listeria monocytogenes-based immunotherapy that targets prostate-specific antigen ( PSA ), is designed to generate antigen-specific T cell...
Nivolumab plus Platinum-doublet chemotherapy vs chemotherapy as first-line treatment for advanced non-small cell lung cancer with less than 1% tumor PD-L1 expression: CheckMate 227
CheckMate 227, a phase 3 study of first-line Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ), Nivolumab, or Nivolumab...
Nivolumab plus Ipilimumab versus Platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: safety analysis from CheckMate 227
CheckMate 227 is a large phase 3 study of first-line Nivolumab plus Ipilimumab, Nivolumab, or Nivolumab plus chemotherapy vs chemotherapy...
Imfinzi is the first immunotherapy for the treatment of locally-advanced, unresectable NSCLC in patients whose tumours express PD-L1 on 1% or more of tumour cells
The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has...
FDA has approved Lumoxiti for the treatment of hairy cell leukemia
The FDA ( U.S. Food and Drug Administration ) has approved Lumoxiti ( Moxetumomab pasudotox-tdfk ) injection for intravenous use...
Combination therapy based on Tafinlar and Mekinist for adjuvant treatment of BRAF V600 mutation-positive melanoma: approved in European Union
The European Commission has approved Tafinlar ( Dabrafenib ) in combination with Mekinist ( Trametinib ) for the adjuvant treatment...
Pembrolizumab: complete response rate of nearly 40% in patients with high-risk non-muscle invasive bladder cancer unresponsive to standard of care
The results from an interim analysis of KEYNOTE-057, a phase 2 trial evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy,...
Pembrolizumab in combination with Axitinib significantly improves overall survival and progression-free survival as first-line therapy for advanced or metastatic renal cell carcinoma
The pivotal phase 3 KEYNOTE-426 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with Axitinib ( Inlyta...
FDA has approved Tagrisso for first-line treatment of metastatic non-small cell lung cancer with most common EGFR mutations
The Food and Drug Administration ( FDA ) has approved Osimertinib ( Tagrisso ) for the first-line treatment of patients...